CorMedix Q1 2025 net revenue $39.1M, net income $20.6M vs loss; raises H1 guidance to high-end

CorMedix Inc.

2025-Q1 EPS reported $0.30 revenue$39,081,657

Q1 net revenue $39.1M; net income $20.6M ($0.32 EPS) vs net loss of $14.5M ($0.25 loss) in Q1 2024.
Adjusted EBITDA $23.6M; cash from operations $19.7M; cash and short-term investments $77.5M at March 31.
Expects to be at high-end of H1 2025 net sales guidance of $62M-$70M based on current order trends.
Inpatient sales team fully staffed; DefenCath inpatient shipments doubled in last 3 months; Phase 3 TPN-CLABSI study started.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.